KS
Therapeutic Areas
ARS Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| neffy® (epinephrine nasal spray) | Emergency treatment of severe allergic reactions (Type I), including anaphylaxis | Approved |
| Intranasal Epinephrine | Acute flares of chronic spontaneous urticaria (CSU) | Preclinical |
Leadership Team at ARS Pharmaceuticals
RL
Richard Lowenthal, M.S., MSEL
President and Chief Executive Officer
ST
Sarina Tanimoto, M.D., M.B.A.
Chief Medical Officer
EK
Eric Karas
Chief Commercial Officer
PS
Pratik Shah, Ph.D.
Chair of the Board of Directors
PK
Peter Kolchinsky, Ph.D.
Director
RD
Rajeev Dadoo, Ph.D.
Director
BS
Brenton Saunders
Director
PS
Phillip Schneider
Director
MK
Michael Kelly
Director
SI
Saqib Islam, J.D.
Director